Tirzepatide vs Semaglutide: Cost Comparison

Updated April 20, 2026

When people ask "which GLP-1 is cheapest," they usually mean one of two drug classes: tirzepatide (sold as Mounjaro, Zepbound, and Foundayo) or semaglutide (sold as Ozempic, Wegovy injection, and Wegovy pill). The short answer in April 2026: the absolute cheapest path is tirzepatide via Foundayo at $149/mo, and the cheapest semaglutide is Wegovy pill at $149/mo on TrumpRx. They tie at the entry price.

Beyond that, the two drug classes diverge in important ways: insurance coverage, dosing structure, formulation options, and clinical evidence. Here's the full breakdown.

What Are They?

Semaglutide

A GLP-1 receptor agonist developed by Novo Nordisk. Mimics the body's natural GLP-1 hormone to reduce appetite and slow gastric emptying. Approved in the U.S. since 2017 for diabetes (Ozempic) and 2021 for chronic weight management (Wegovy).

Brand names:

• Ozempic — weekly injection, approved for Type 2 diabetes, cardiovascular risk, kidney disease
• Wegovy injection — weekly injection, approved for weight management
• Wegovy pill — daily oral, approved for weight management (launched Dec 2025)
• Rybelsus — original oral semaglutide for diabetes, less commonly prescribed now

Tirzepatide

A dual GIP/GLP-1 receptor agonist developed by Eli Lilly. Activates two receptors instead of one, which produces somewhat greater appetite suppression and weight loss in head-to-head trials. Approved in the U.S. since 2022.

Brand names:

• Mounjaro — weekly injection, approved for Type 2 diabetes, sleep apnea
• Zepbound — weekly injection, approved for weight management, sleep apnea
• Foundayo (orforglipron) — daily oral, approved for weight management (launched April 2026). Technically a different molecule (orforglipron is a non-peptide small molecule, not tirzepatide), but a new-generation tirzepatide alternative in the same class of dual-action agonists.

Price by Brand (Self-Pay, 2026)

Cheapest Tirzepatide: Foundayo at $149/mo

Foundayo launched April 2026 at a $149/mo starting price through LillyDirect and Amazon Pharmacy. At maintenance doses, the price rises to $299–$349/mo. It's a daily pill with no food restrictions, making it more convenient than Wegovy pill. If the tirzepatide drug class is what your doctor recommends, Foundayo is the cheapest entry point.

Zepbound ($299/mo TrumpRx) is the cheapest injectable tirzepatide. Mounjaro ($350/mo TrumpRx) is the most expensive tirzepatide option for self-pay patients.

Cheapest Semaglutide: Wegovy Pill at $149/mo

Wegovy pill on TrumpRx is flat $149/mo at every dose, including maintenance. That's the floor for brand-name semaglutide in 2026. Wegovy injection ($199/mo TrumpRx) and Ozempic ($199–$350/mo TrumpRx, dose-dependent) come in above.

The Wegovy pill has a specific catch: it must be taken on an empty stomach with no more than 4 oz of water, and nothing else for 30 minutes. For some people that's trivial; for others it's a dealbreaker. Foundayo doesn't have this restriction.

Insurance Coverage: Semaglutide Has the Track Record

Ozempic has been on insurance formularies since 2018, Wegovy injection since 2022, and both have established prior-authorization workflows at every major insurer. Commercial coverage rates run ~82% for Ozempic (diabetes indication), ~60–70% for Wegovy injection (weight management).

Tirzepatide is newer. Commercial coverage for Mounjaro (diabetes) reaches ~82%, but Zepbound (weight management) lags at 30–40%. Foundayo is so new that formal coverage decisions are still pending at most insurers.

If you need insurance to pay, semaglutide (Ozempic) has the best odds. If you're paying cash, tirzepatide (Foundayo) is the cheapest.

Clinical Effectiveness: Tirzepatide Edges Ahead

Head-to-head trials (SURMOUNT-5, published 2024) showed tirzepatide producing somewhat greater average weight loss than semaglutide — roughly 20% of baseline body weight at maintenance doses vs. 15% for semaglutide. Both are highly effective compared to lifestyle alone. Individual response varies significantly, so the "better" drug for any specific patient depends on factors beyond the average.

For diabetes A1C reduction, the two are roughly equivalent in clinical trials.

When to Choose Tirzepatide

• Paying cash and want the absolute lowest price (Foundayo $149/mo).
• Prioritizing weight loss effectiveness — tirzepatide shows slightly greater weight loss in trials.
• Have obstructive sleep apnea — both Mounjaro and Zepbound carry FDA approval.
• Want an oral GLP-1 without food restrictions — Foundayo is the only option that qualifies.

When to Choose Semaglutide

• Need insurance to cover it — better track record of coverage decisions.
• Have Type 2 diabetes and commercial insurance — Ozempic savings card brings copay to $25/mo.
• Need a lower-cost injectable — Wegovy injection at $199/mo on TrumpRx beats tirzepatide injectables.
• Have a cardiovascular or kidney disease indication — Ozempic is FDA-approved for both.

The Decision Framework

1. Is your insurance likely to cover it? If yes, go semaglutide (better coverage odds). Use savings card, pay $25/mo.
2. Paying cash and want absolute cheapest? Foundayo (tirzepatide class) or Wegovy pill (semaglutide) at $149/mo. Tie.
3. Paying cash and prefer an injection? Wegovy injection at $199/mo TrumpRx is cheaper than either tirzepatide injectable.
4. Paying cash and want the most effective option? Tirzepatide (Foundayo, Zepbound, or Mounjaro) has slightly greater weight loss in trials.